Insider Selling: Dyadic International (NASDAQ:DYAI) Major Shareholder Sells 20,000 Shares

Dyadic International Inc. (NASDAQ:DYAI) major shareholder Francisco Trust Under Agreemen sold 20,000 shares of the company’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $1.92, for a total transaction of $38,400.00. Following the transaction, the insider directly owned 3,390,664 shares of the company’s stock, valued at approximately $6,510,074.88. This represents a 0.59% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Dyadic International Price Performance

DYAI opened at $0.94 on Monday. Dyadic International Inc. has a 1 year low of $0.65 and a 1 year high of $1.35. The company’s 50 day simple moving average is $0.77 and its 200 day simple moving average is $0.83. The stock has a market capitalization of $34.27 million, a PE ratio of -4.09 and a beta of 1.15. The company has a debt-to-equity ratio of 4.08, a quick ratio of 2.42 and a current ratio of 2.42.

Dyadic International (NASDAQ:DYAI) last posted its quarterly earnings results on Wednesday, May 13th. The biotechnology company reported ($0.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.01). Dyadic International had a negative return on equity of 1,005.45% and a negative net margin of 192.40%.The company had revenue of $1.11 million for the quarter, compared to analysts’ expectations of $0.90 million. As a group, sell-side analysts expect that Dyadic International Inc. will post 0.13 EPS for the current year.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Dyadic International in a research report on Wednesday, June 24th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Dyadic International has an average rating of “Hold” and a consensus price target of $3.00.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Bank of America Corp DE boosted its position in shares of Dyadic International by 16,146.7% in the fourth quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock worth $47,000 after buying an additional 26,965 shares during the period. Landscape Capital Management L.L.C. acquired a new stake in shares of Dyadic International in the third quarter valued at about $190,000. Marathon Capital Management purchased a new stake in shares of Dyadic International during the 3rd quarter valued at about $41,000. Apis Capital Advisors LLC purchased a new stake in shares of Dyadic International during the 3rd quarter valued at about $1,817,000. Finally, Geode Capital Management LLC lifted its position in Dyadic International by 13.7% during the 4th quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock worth $284,000 after acquiring an additional 36,266 shares in the last quarter. Institutional investors and hedge funds own 27.95% of the company’s stock.

Dyadic International Company Profile

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.